$WBA

The ASSIST Act of 2025, favorably reported by the Committee on Veterans' Affairs, expands healthcare access and support for veterans. This creates direct revenue opportunities for healthcare providers, diagnostic companies, and technology firms specializing in veteran services. Investors should anticipate increased contract awards in these areas.

The End Veterans Overdose Act of 2026, advancing through the Senate Veterans' Affairs Committee, directs increased funding towards opioid addiction treatment and prevention for veterans. This creates a direct revenue stream for pharmaceutical companies producing addiction treatments and healthcare providers specializing in substance abuse services.

The 'Improving Access to Care for Rural Veterans Act' (S3033) advances, indicating increased federal spending on rural veteran healthcare. This bill directly benefits pharmaceutical companies, medical device manufacturers, and healthcare providers with rural presences, as it expands access to care and associated services.

This bill directly targets the availability of mifepristone, a key drug in reproductive healthcare. Its passage would eliminate a significant market for pharmaceutical companies and could increase demand for other healthcare services.

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (S.242) ensures continued funding and strategic direction for public health emergency preparedness. This bill maintains existing support for pharmaceutical companies, medical device manufacturers, and healthcare service providers involved in national health security.

The Treat and Reduce Obesity Act of 2025 expands Medicare coverage for obesity treatments, directly benefiting pharmaceutical companies producing GLP-1 agonists and medical device manufacturers. This legislation significantly increases the total addressable market for these therapies.

The BUST FENTANYL Act, S860, targets the fentanyl crisis through enhanced detection and interdiction. This bill increases demand for drug screening technologies, laboratory services, and pharmaceutical countermeasures, directly benefiting companies in these sectors.

The 'Protecting Students on Campus Act of 2025' is a procedural referral to committee, indicating early legislative stage. This bill targets campus safety and student well-being, impacting companies providing related services and products. No immediate market movement is expected.

The Medical Supply Chain Security Act (HR6049) aims to bolster domestic medical supply production and reduce reliance on foreign sources. This will directly benefit U.S.-based medical device and pharmaceutical manufacturers, increasing their market share and contract opportunities. Healthcare providers will also see improved supply stability.

The PREEMIE Reauthorization Act of 2025 focuses on research and interventions for preterm birth. This bill provides continued, stable funding for existing programs, preventing a lapse in federal support for maternal and infant health initiatives. No new significant market opportunities are created, but existing beneficiaries maintain their revenue streams.

HR1867 eliminates in-person requirements for Medicare mental health telehealth services, expanding access and increasing revenue opportunities for telehealth providers. This directly benefits companies offering virtual mental health platforms and services.

The Reducing Hereditary Cancer Act, HR4752, directs significant resources towards genetic testing and counseling for hereditary cancer. This creates a direct revenue stream for genetic testing companies and healthcare providers specializing in cancer diagnostics and prevention.

The Protecting Employees and Retirees in Business Bankruptcies Act of 2025 increases employee claims in Chapter 11 bankruptcies, raising costs for companies undergoing reorganization and increasing risk for lenders. This shifts financial burden from employees to corporate balance sheets and creditors. Companies with high labor costs and those in cyclical industries face increased bankruptcy liabilities.

The Medicare for All Act, if enacted, eliminates private health insurance and significantly reduces revenue for pharmaceutical and medical device companies. This bill creates a single-payer system, shifting all healthcare spending to the federal government and directly impacting the profitability of current healthcare providers and insurers.

The Combating Organized Retail Crime Act of 2025 moves forward, signaling increased federal intervention against retail theft. This directly benefits major retailers by reducing losses and boosts demand for security technology providers.

The Medical Nutrition Therapy Act of 2026 expands Medicare coverage for medical nutrition therapy, directly increasing demand for registered dietitian services and related products. This bill creates a new revenue stream for healthcare providers and nutrition-focused companies. The market will see increased utilization of nutrition services.